Why Tango Therapeutics, Inc.’s (TNGX) Stock Is Down 8.63%
As of Thursday, November 05, Tango Therapeutics, Inc.’s TNGX share price has dipped by 8.63%, which has investors questioning if this is right time to buy.Michael Rose
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Tango Therapeutics, Inc., a precision oncology company, focuses on the discovery and development of drugs in defined patient populations with unmet medical need. The company develops methylthioadenosine -cooperative protein arginine methyltransferase 5 (PRMT5) inhibitors, including TNG462, which is in Phase 1/2 clinical trial for treating pancreatic and lung cancer; and TNG456, a brain-penetrant PRMT5 inhibitor for the treatment of glioblastoma. It is developing TNG260, a co-repressor of repressor element-1 silencing transcription inhibitor to reverse the immune evasion effect of serine-threonine kinase (STK) 11 loss-of-function mutations to treat lung cancer. The company was founded in 2017 and is headquartered in Boston, Massachusetts.
Commentary & Analysis
Why Tango Therapeutics, Inc.’s (TNGX) Stock Is Up 8.62%
As of Tuesday, November 03, Tango Therapeutics, Inc.’s TNGX share price has surged by 8.62%, which has investors questioning if this is right time to sell.Rosalio Madrigal
Which Is a Better Investment, Tango Therapeutics, Inc. or Vir Biotechnology, Inc. Stock?
Learn more about whether Tango Therapeutics, Inc. or Vir Biotechnology, Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.Tudor Pop
Why Tango Therapeutics, Inc.’s (TNGX) Stock Is Up 5.15%
As of Thursday, October 29, Tango Therapeutics, Inc.’s TNGX share price has surged by 5.15%, which has investors questioning if this is right time to sell.Tudor Pop
Why Tango Therapeutics, Inc.’s (TNGX) Stock Is Down 16.97%
As of Friday, October 23, Tango Therapeutics, Inc.’s TNGX share price has dipped by 16.97%, which has investors questioning if this is right time to buy.Michael Rose
Financial Summary
| Share Statistics | TNGX | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $3,625.1 | $219.9 | 63% |
|
| Shares Out (Mil) | 149.9 | 54.1 | 70% |
|
| Institutional Ownership | 98.9% | 92.9% | 83% |
|
| Float (Mil) | 120.7 | 41.4 | 64% |
|
| Beta | 1.15 | 0.95 | 68% |
|
| Avg Daily Volume (000s) | 3,479 | 522 | 87% |
|
| Price Change (52-week) |
186.3% | 44.7% | 99% |
|
| Growth | TNGX | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | 52.0% | 13.2% | 96% |
|
| Net Income (5yr) | (14.3%) | (10.1%) | 26% |
|
| EPS (5yr) | 11.7% | 15.8% | 50 |
|
| Dividends (5yr) | 0.0% | 0.0% | 0% |
|
| Cash Flow (5yr) | 16.8% | (15.7%) | 76% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 12 | 12 | 11 | |
| Current EPS | ($0.351) | ($1.395) | ($1.685) | |
| Month Ago EPS | ($0.351) | ($1.396) | ($1.685) | |
| # Rev Up | 0 | 1 | 0 | |
| # Rev Down | 1 | 1 | 1 | |
| Three Months Ago EPS | ($0.330) | ($1.294) | ($1.520) | |
| Year/Year Chg | (4.9%) | 59.4% | 120.3% | |
| Financials | TNGX | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $54 | $38 | 21% |
|
| Net Income (TTM) (Mil) | ($124) | ($44) | 9% |
|
| EPS (TTM) | ($0.915) | ($1.500) | 22% |
|
| Operating Cash Flow (TTM) (Mil) | ($144) | ($35) | 5% |
|
| Net Cash Flow (TTM) (Mil) | $306 | $0 | 87% |
|
| Long-Term Debt (Q1) (Mil) | $29 | $4 | 35% |
|
| Enterprise Value (Q1) (Mil) | $3,459 | $166 | 57% |
|
| Valuation | TNGX | Industry Median |
Percentile (All Stocks) |
|
| P/B | 3.54 | 2.06 | 73% |
|
| P/E | na | 16.5 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 0.9 | na |
|
| Ratios | TNGX | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | (148.4%) | 67.3% | 2% |
|
| Net Margin | (229.9%) | (61.0%) | 4% |
|
| ROA | (18.9%) | (47.5%) | 20% |
|
| ROE | (21.3%) | (52.7%) | 23% |
|
| Liabilities to Assets | 4.6% | 29.6% | 2% |
|
| F-Score | 4 | 3 | 33% |
|
Tango Therapeutics, Inc. did not pass any screens on 11/6/2026.
